SCHEMBL12437178

SCHEMBL12437178

CCN(CCCC(C)(C)C)Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.53
CHRM2 P08172 1/20 0.53
HTR1A P08908 1/20 0.53
ADRA2A P08913 1/20 0.53
CHRM1 P11229 1/20 0.53
DRD1 P21728 1/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A4 P31645 1/20 0.53
ADRA1A P35348 1/20 0.53
OPRM1 P35372 1/20 0.53
DRD3 P35462 1/20 0.53
SLC6A3 Q01959 1/20 0.53
MAOB P27338 4/20 0.52
BCHE P06276 4/20 0.51
ACHE P22303 3/20 0.51
APP P05067 2/20 0.47
CACNA2D1 P54289 1/20 0.47
KDM4E B2RXH2 1/20 0.46
CNR2 P34972 1/20 0.46
SIGMAR1 Q99720 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13656288 0.89 MAOB (0.50) KCNH2CHRM2HTR1AADRA2ACHRM1
SCHEMBL28955041 0.83 MEN1 (0.49) ACHEKDM4ETSHRMAPK1
SCHEMBL9485143 0.82 KCNH2 (0.61) KCNH2CHRM2HTR1AADRA2ACHRM1
SCHEMBL12126329 0.80 KCNH2 (0.81) KCNH2CHRM2HTR1AADRA2ACHRM1
SCHEMBL12126085 0.80 KCNH2 (0.69) KCNH2CHRM2HTR1AADRA2ACHRM1
SCHEMBL10287670 0.79 BCHE (0.48) KCNH2CHRM2HTR1AADRA2ACHRM1
SCHEMBL22749466 0.79 MAOB (0.57) KCNH2CHRM2HTR1AADRA2ACHRM1
SCHEMBL12126534 0.79 KCNH2 (0.72) KCNH2CHRM2HTR1AADRA2ACHRM1
SCHEMBL9278088 0.79 KCNH2 (0.72) KCNH2CHRM2HTR1AADRA2ACHRM1
SCHEMBL3322548 0.79 KCNH2 (0.56) KCNH2CHRM2HTR1AADRA2ACHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-09-30 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF TP53, BCOR, HPGDS KCNH2 4836/4885CHRM2 4877/4885HTR1A 4730/4885
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof HPGDS, HPGD, DPYD KCNH2 4831/4885CHRM2 4850/4885HTR1A 3457/4885
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof HPGDS, HPGD, DPYD KCNH2 4831/4885CHRM2 4850/4885HTR1A 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.